Announcements Trials

Browse Landscape

Phase

Status

Terminated 2 Completed 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2 Urologic Diseases 1 Pancreatic Neoplasms 1 Nephritis 1 Neoplasms 1 Melanoma 1 Mastocytosis 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Kidney Diseases 1 Immune System Diseases 1 Hypoxia 1 Glomerulonephritis, IGA 1 Glomerulonephritis 1 Carcinoma, Non-Small-Cell Lung 1 COVID-19 1 Autoimmune Diseases 1

Interventions

Exercise 19 Drug Therapy 18 pembrolizumab 13 Capecitabine 11 Blood Specimen Collection 11 Surveys and Questionnaires 10 Radiotherapy 10 Paclitaxel 9 Dexamethasone 9 Nivolumab 8 Standard of Care 7 Oxaliplatin 7 Fluorouracil 7 Erlotinib Hydrochloride 7 apatinib 6 Interviews as Topic 6 Gemcitabine 6 Control Groups 6 Cisplatin 6 Therapeutics 5 Neoadjuvant Therapy 5 Mindfulness-Based Cognitive Therapy 5 Metformin 5 Injections 5 Everolimus 5 Docetaxel 5 Cyclophosphamide 5 Bevacizumab 5 sintilimab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Neoplasms × Hydroxychloroquine × Clear all

NCT04341207 2020-04-10

ONCOVID

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Unknown

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡